Which is true of cluster headaches? (Select all that apply)

Ergotamine and other ergot-derived antimigraine medications cause vasoconstriction by stimulating serotonin and adrenergic receptors in vascular smooth muscle. Excessive dosing or prolonged use can lead to systemic vasospasm, reducing blood flow to the extremities. This can produce ischemic symptoms such as cold, pale limbs and paresthesia. Recognizing drug-induced vascular complications is essential in patients being treated for migraine disorders.

Rationale:
A. Ergotamine withdrawal is not a recognized clinical syndrome. Unlike dependence-producing substances, ergot derivatives do not cause a classic withdrawal pattern characterized by rebound systemic symptoms. The presentation of cold, pale extremities suggests vasoconstriction rather than withdrawal effects.

B. Severe migraine symptoms typically include unilateral pulsating headache, nausea, photophobia, and phonophobia. While migraines can cause neurologic symptoms such as aura, they do not cause peripheral ischemic signs like cool, pale extremities.

C. Ergotism is caused by excessive exposure to ergot-derived medications such as ergotamine. It results in intense peripheral vasoconstriction leading to ischemia, numbness, cold extremities, and pallor. Severe cases may progress to gangrene if not promptly recognized and treated by discontinuing the offending agent.

D. Sumatriptan side effects typically include transient sensations such as flushing, dizziness, or chest tightness due to vasoconstrictive activity, but it rarely causes severe peripheral ischemia. The symptoms described (cool, pale hands and feet with numbness) are more consistent with prolonged ergot-induced vasospasm rather than triptan adverse effects.

Management of patients on antidepressant therapy such as Selective serotonin reuptake inhibitors requires close monitoring for worsening depression and emergence of suicidal ideation, especially in young adults. Early in treatment, increased energy may precede improvement in mood, potentially elevating suicide risk in high-risk individuals. A patient with a concrete plan and history of prior attempts represents an acute psychiatric emergency. Safety becomes the immediate priority over medication adjustments or outpatient follow-up.

Rationale:
A. Changing the medication to another drug class may be considered later, but it does not address the immediate risk of self-harm. Antidepressant adjustments take time to show effect and do not provide rapid protection against suicide risk. The priority is ensuring patient safety rather than modifying pharmacologic therapy at this stage.

B. Discontinuing the medication immediately is not the priority intervention and may worsen withdrawal symptoms or depressive symptoms. Abrupt cessation of SSRIs can also lead to discontinuation syndrome, including agitation and mood instability. The immediate concern is stabilization and protection of the patient rather than sudden pharmacologic changes.

C. Requiring more frequent clinic visits may be appropriate for mild risk situations, but it is insufficient in the presence of an active suicide plan and prior attempts. Outpatient management does not provide the level of supervision needed to prevent imminent self-harm. The severity of risk exceeds what can be safely managed in a clinic setting.

D. Hospitalizing the patient for closer monitoring is the priority action due to the presence of a concrete suicide plan and a history of prior attempts. Inpatient care allows continuous observation, environmental safety control, and rapid psychiatric intervention. It ensures immediate protection while treatment adjustments and comprehensive risk management are initiated.